CME GROUP INC.
For the period ended Mar 31, 2026. Filed Apr 24, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Apr 24, 2026
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2025-09-30; filed 2025-10-24.
0001156375-25-000206
Item 1A. Risk FactorsUnregistered Sales of Equity Securities and Use of ProceedsCurrent report: 10-Q
Period ended 2026-03-31; filed 2026-04-24.
0001156375-26-000020
Item 1A. Risk FactorsUnregistered Sales of Equity Securities and Use of ProceedsThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 4 previous paragraphs and 6 current paragraphs.
2 unchanged; 2 reworded; 2 added; 0 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 3 previous and 3 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Added paragraphs (2)
Current report
(2)Includes an aggregate of 514 shares of Class A common stock surrendered to satisfy employees' tax obligations upon the vesting of restricted stock.
Current report
(3)Includes an aggregate of 70,170 shares of Class A common stock surrendered to satisfy employee's tax obligations upon the vesting of restricted stock.
Reworded paragraphs (2)
Previous wording
(1)On December 5, 2024, CME Group announced that its board of directors approved a share repurchase program under which CME Group is authorized to repurchase up to $3.0 billion of its outstanding Class A common stock, par value $0.01 per share (the common stock). The share repurchase program has no expiration date.
Current wording
(1)CME Group maintains a share repurchase program under which CME Group is authorized to repurchase up to $3.0 billion of its outstanding Class A common stock, par value $0.01 per share (the common stock) as announced on December 5, 2024. The share repurchase program has no expiration date.
Previous wording
(2)Shares purchased consist of shares surrendered to satisfy employee tax obligations upon the vesting of restricted stock.
Current wording
(4)Shares purchased includes an aggregate of 70,684 shares of Class A common stock surrendered to satisfy employee tax obligations upon the vesting of restricted stock.